

Sun Pharmaceutical Industries Ltd.

Sun House, Plot No. 201 B/1,
Western Express Highway, Goregaon (E),
Mumbai - 400 063, Maharashtra, INDIA,
Tel. : (91-22) 4324 4324
Fax : (91-22) 4324 4343
www.sunpharma.com
CIN : L24230GJ1993PLC019050



May 23, 2016

1. National Stock Exchange of India Ltd,
Exchange Plaza, 5th Floor,
Plot No. C/1, G Block,
Bandra Kurla Complex,
Bandra (East), Mumbai – 400 051.
Scrip Name: SUNPHARMA
2. BSE Ltd,
Market Operations Dept.
P. J. Towers, Dalal Street,
Mumbai - 400 001.
Scrip Code:524715

Sub : Receipt of request letter(s) along with Undertaking(s) from certain Promoter Group persons/entities for Reclassifying them as Public as permitted under Listing Regulation 31A of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015


Dear Sir/Madam,

This is to inform you that the Company has received request letter(s) cum Undertaking from the following persons/entities forming part of the promoter/promoter group of the Company as on date for Reclassifying them from “Promoter Category” to “Public Category” as permitted under the provisions of Regulation 31A(7) of the SEBI (Listing Obligation & Disclosure Requirements) Regulations, 2015.

- a. Mr. Jayant Shantilal Sanghvi
- b. Pratham Investments
- c. Mr. Ajay Vrundavandas Valia
- d. Mr. Kirit Valia
- e. Kirit V. Valia (HUF)
- f. Mr. Jitendra Vrundavandas Valia
- g. Jitendra V Valia (HUF)
- h. Ms. Dipti Modi
- i. Ms. Varsha Doshi

Please note that the current shareholding in the Company of the aforesaid entities/persons is less than 1% of the total paid up capital of the Company, individually and collectively and they do not exercise any control over the Company and are also not engaged in the management and/or day to day affairs of the Company.

Further they have also informed that they do not hold any representation on the Board nor hold any special right/voting rights through formal or informal arrangements with the Company or with the Promoter of the Company.



The aforesaid applications will be considered by the Board at its ensuing meeting to be held on Monday, 30th May, 2016 subject to approval of the Shareholders and necessary approvals from the SEBI Board/Stock Exchanges in accordance with the provisions of Regulation 31A(7) of the SEBI (Listing Obligation & Disclosure Requirements) Regulations, 2015

This is for your information and record.

Thanking you,

Yours faithfully,
For **Sun Pharmaceutical Industries Ltd.**,



Ashok I. Bhuta
Compliance Officer

